1. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Доступно на: http://www.thoracic.org/sections/publications/statements/pages/mtpi/idsaats-cap.html
2. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–80.
3. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. М.: 2010.
4. Macfarlane J. An overview of community-acquired pneumonia with lessons learned from the British Thoracic Society Study. Semin Respir Infect 1994; 9: 153–65.
5. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997; 10: 1530–4.
6. Lee R, Lindstrom S. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology 2007; 12 (1): 111–6.
7. Garcia-Vidal C, Carratalà J, Díaz V et al. Factors associated with prolonged hospital stay in community-acquired pneumonia. Enf Inf Microb Clin 2009; 27 (3): 160–4.
8. Niederman M. Cost-effective antibiotic management of community-acquired pneumonia. Eur Respir Mon 2004; 28: 198–210.
9. Raut M, Schein J, Mody S et al. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin 2009; 25 (9): 2151–7.
10. Niederman M, McCombs J, Unger A et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820–37.
11. Brown R, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia:analysis of a hospital claims-made database. Chest 2003; 23: 1503–11.
12. Menendez R, Torres A, Zalacain R et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960–5.
13. Amsden GW. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10–21.
14. Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions. Аnn Pharmacother 1998; 32 (7–8): 785–93.
15. Ball P. Therapeutic considerations for the management of respiratory tract infections. The role of new macrolides and fluoroquinolones. Infect In Med 1991; 8 (Suppl. A): 7–17.
16. Williams JD, Sefton AM. Comparison of macrolide antibiotics. J Antimicrob Chemother 1993; 31 (Suppl. C): 11–26.
17. Odenholt-Tornqvist I, Lowdin E, Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother 1995; 39: 221–6.
18. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander project. J Antimicrob Chemother 2000; 46 (1): 3–9.
19. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. КМАХ. 2006; 1 (8): 33–47.
20. Решедько Г.К., Козлов Р.С. Состояние резистентности к антиинфекционным химиопрепаратам в России. В кн.: Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.И.Козлова. М., 2007; с. 32–47.
21. Zuckerman J.M. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 2004; 18 (3): 621–49.
22. Thakker K, Caridi F, Powell M et al. Multiple-dose pharmacokinetics of azithromycin following 1-hour intravenous infusions in hospitalized patients with community-acquired pneumonia. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Canada, 1997.
23. Luke D, Foulds G, Cohen S et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob. Agents Chemother 1996; 40: 2577–81.
24. Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. New York, etc., 1995; p. 51–60.
25. Gialdroni Grassi G, Grassi C. Clinical application of macrolides and azalides in Legionella, Mycoplasma, and Chlamydia respiratory infections. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Eds: H.Neu, L.Young, S.Zinner, J.Acar. New York, etc., 1995; p. 147–54.
26. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125: 41–51.
27. Culic O, Erakovich V, Pamham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209–29.
28. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005; 18: 125–31.
29. Tateda K, Ishii Y, Matsumoto T et al. Direct evidence for antipseudomonal activity of macrolides; exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob. Agents Chemother 1996; 40: 2271–5.
30. Culic O, Erakovic V, Cepelak I et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002; 450: 277–89.
31. Zimmermann T, Riedel K, Laufen H et al. Intravenous toleration of azithromycin in comparison to clarithromycin and erythromycin. In: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996; p. A82.
32. Plouffe J, Schwartz D, Kolokathis A et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 2000; 44 (7): 1796–802.
33. Wilton L, Kollarova M, Heeley E, Shakir S. Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. Drug Saf 2003; 26 (8): 589–97.
34. Vergis EN, Indorf А, File MМ et аl. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of соmmunity-acquired pneumonia in hospitalized patients: Аprospective, randomized, multicenter trial. Arch Intern Med 2000; 160 (9): 1294–300.
35. Paladino JA, Gudgel LO, Forrest А, Niederman MS. Cost-effectiveness of IV-to-oral switch therapy: Azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002; 122 (4): 1271–9.
36. Kuzman, Dakovic-Rode O, Oremus M, Banaszak AM. Clinical Efficacy and Safety of a Short Regimen of Azithromycin Sequential Therapy vs Standard Cefuroxime Sequential Therapy in the Treatment of Community-Acquired Pneumonia: An International, Randomized, Open-Label Study. Chemotherapy 2005; 17 (6): 363–42.

А.И.Синопальников1, А.А.Зайцев2 

1 ГОУ ДПО Российская медицинская академия последипломного образования Минздравсоцразвития РФ;
2 Главный военный клинический госпиталь имени академика Н.Н.Бурденко